Welcome to our dedicated page for ICU Medical news (Ticker: ICUI), a resource for investors and traders seeking the latest updates and insights on ICU Medical stock.
ICU Medical Inc. (NASDAQ: ICUI) is dedicated to creating connections in healthcare. Headquartered in San Clemente, California, the company is a leader in designing and manufacturing some of the world's safest, most reliable medical devices and systems for infusion therapy, oncology, and critical care applications. ICU Medical’s extensive product line includes needle-free vascular access devices, custom infusion systems, closed delivery systems for hazardous drugs, advanced sensor catheters, and hemodynamic monitoring systems.
Founded on the principle of improving patient outcomes, ICU Medical's products help prevent bloodstream infections and protect both patients and healthcare workers from exposure to infectious diseases and hazardous drugs. The company has significantly expanded its market presence through strategic acquisitions, including Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022.
ICU Medical operates through three major segments: consumables, infusion systems, and vital care, contributing 43%, 28%, and 29% of consolidated revenue respectively. The company primarily serves the U.S. market, which accounts for over 63% of its sales. Their commitment to safety and quality ensures essential human and emotional connections between patients and caregivers, enhancing clinical experiences and overall quality of care.
Recent achievements underscore ICU Medical's robust financial performance. For the second quarter of 2023, the company reported revenues of $549.3 million with a GAAP gross profit of $192.3 million, marking a significant improvement in gross margin to 35% from the previous year’s 30%. Despite a GAAP net loss of $9.9 million, the adjusted diluted earnings per share were noted at $1.88, marking an increase from $1.37 year-over-year. The third-quarter results continued this positive trend with revenue reaching $553.3 million, though GAAP net income was recorded at $7.2 million.
For fiscal year 2023, ICU Medical has provided guidance, expecting GAAP net losses to range between $59 million and $38 million, alongside a forecasted adjusted EBITDA between $375 million and $405 million. The company's strategic focus remains on integrating acquisitions and enhancing operational efficiencies to drive future growth.
ICU Medical is not only a significant player in the medical device industry but also a beacon of innovation and quality, continually striving to meet the evolving needs of healthcare providers and patients globally.
ICU Medical, Inc. (Nasdaq:ICUI) announced the timing of its second quarter 2022 earnings release and conference call. The earnings results will be disclosed on August 8, 2022, at approximately 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. Stakeholders can access the call at (877) 300-8521, using conference ID 10169518. A webcast will also be available on the company's website. ICU Medical specializes in infusion systems and critical care products, catering to hospital and home care settings.
ICU Medical reported strong financial results for Q1 2022, with revenue reaching $543.1 million, up $225.1 million from $318.0 million in Q1 2021. GAAP gross profit stood at $168.8 million (31% gross margin) compared to $112.7 million (35% margin) the previous year. However, the company faced a GAAP net loss of $(38.1) million or $(1.61) per share, contrasting with net income of $23.7 million in Q1 2021. Adjusted diluted EPS improved to $1.82, while adjusted EBITDA rose to $84.9 million.
ICU Medical, Inc. (Nasdaq: ICUI) has scheduled its first quarter 2022 earnings release for May 9, 2022, at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. The call will be accessible by phone at (877) 407-3982 and will also be streamed live via the company's website. ICU Medical specializes in infusion systems and critical care products used in various healthcare settings. The company emphasizes its commitment to quality and innovation for clinical customers worldwide.
SAN CLEMENTE, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- ICU Medical, a leader in innovative medical products, will participate in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum on March 22, 2022, at 8:15 a.m. PT (11:15 a.m. ET). The chat will be webcast live on the company's website and will include one-on-one meetings with investors on the same day. ICU Medical is recognized for its infusion systems and critical care products used globally in various healthcare settings.
ICU Medical, a leader in innovative medical products, announced its participation in a fireside chat at the Raymond James 43rd Annual Institutional Investors Conference. This event is scheduled for March 8, 2022, at 11:15 a.m. PT (2:15 p.m. ET). ICU Medical focuses on infusion systems and critical care products, serving hospitals and home care settings globally. The company aims to provide quality and innovation to its clinical customers. For more details, visit icumed.com.
ICU Medical, Inc. (Nasdaq:ICUI) reported fourth quarter 2021 revenue of $340.5 million, up from $320.5 million the previous year. GAAP gross profit rose to $127.5 million with a stable gross margin of 37%. The company posted a GAAP net income of $19.9 million ($0.91 per diluted share), down from $26.1 million ($1.21 per diluted share) year-over-year. Adjusted diluted EPS improved to $1.82 from $1.77. Looking ahead, ICU Medical expects adjusted EBITDA for fiscal 2022 between $450 million and $500 million, with adjusted diluted EPS ranging from $9.00 to $10.50.
ICU Medical (Nasdaq:ICUI) announced the schedule for its fourth quarter 2021 earnings release and conference call. The company will publish its results on February 24, 2022, at approximately 4:00 p.m. ET. A conference call will follow at 4:30 p.m. ET, accessible at (855) 327-6837 with conference ID 10017891. The call will also be available via webcast on the company's website. ICU Medical specializes in infusion systems and critical care products and is headquartered in San Clemente, California.
ICU Medical (NASDAQ: ICUI) has successfully acquired Smiths Medical from Smiths Group (LSE: SMIN.L), enhancing its position in the infusion therapy market. The combined revenue is projected at approximately $2.5 billion. This acquisition aims to create a scalable US-based competitor, improving supply chain stability and allowing for growth aligned with evolving clinical care models. ICU Medical plans to announce its complete FY 2022 guidance during its Q4 earnings call in late February.
ICU Medical (Nasdaq: ICUI) will present at the J.P. Morgan 40th Annual Healthcare Conference, scheduled from January 10-13, 2022. The presentation is set for January 12, 2022, at 10:30 a.m. PST (1:30 p.m. EST). Investors can access the live webcast on the company's website under the Investors tab. ICU Medical focuses on innovative products for infusion therapy and critical care, including IV smart pumps and closed system transfer devices. More details are available at www.icumed.com.
ICU Medical (Nasdaq:ICUI) reported a revenue increase of $336.1 million for the third quarter of 2021, up from $318.6 million in Q3 2020. The GAAP net income rose to $31.1 million, or $1.43 per diluted share, compared to $25.0 million, or $1.16 per diluted share, in the same quarter last year. Adjusted diluted EPS also increased to $2.07 from $1.90. The GAAP gross profit was $127.8 million with a gross margin of 38%. Notably, infusion consumables saw a significant increase, while IV solutions experienced a decline.
FAQ
What is the current stock price of ICU Medical (ICUI)?
What is the market cap of ICU Medical (ICUI)?
What does ICU Medical Inc. specialize in?
Where is ICU Medical Inc. headquartered?
What are the major segments of ICU Medical Inc.’s business?
What significant acquisitions has ICU Medical Inc. made?
How does ICU Medical Inc. contribute to patient safety?
What was ICU Medical Inc.’s revenue for the second quarter of 2023?
What is the geographic focus of ICU Medical Inc.’s sales?
What guidance has ICU Medical Inc. provided for fiscal year 2023?
What was ICU Medical Inc.’s adjusted diluted earnings per share for the second quarter of 2023?
How does ICU Medical Inc. foster human and emotional connections in healthcare?
